Figure 2 | Cell Death & Disease

Figure 2

From: Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin–NFAT pathway

Figure 2

Activated CD8 T cells are resistant to ABT-737 in a GvH model. BM3.3 splenocytes were adoptively transferred to CBA (syngeneic) or (CBA × B6)F1 (allogeneic) recipients to assess the effect of ABT-737 on GvH-reactive cells. After 3 daily injections of ABT-737 (filled circles) or vehicle (open circles), splenocytes were analyzed by FACS. (a and b) Allogeneic CD8 T-cell activation was confirmed by CD25 expression and (c and d) a selective analysis of Ti98+ cells indicated that ABT-737 did not substantially influence this process. (e and f) A similar reduction in the number of total splenocytes was registered in both groups (about 30% reduction, please note the different total number of splenocytes in different recipient strains). (g and h) The total number of Ti98+ cells decreased in the syngeneic, but not in the allogeneic combination, indicating resistance to ABT-737 in allo-activated CD8 T cells. Statistical comparison ABT-737 versus vehicle; *P<0.05, **P<0.01, ***P<0.001; n=5. Representative results of one of two independent experiments are shown

Back to article page